Published in Ecancermedicalscience on August 28, 2014
Disruption of actin filaments and suppression of pancreatic cancer cell viability and migration following treatment with polyisoprenylated cysteinyl amides. Am J Cancer Res (2016) 0.75
The antiangiogenic effects of polyisoprenylated cysteinyl amide inhibitors in HUVEC, chick embryo and zebrafish is dependent on the polyisoprenyl moiety. Oncotarget (2016) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res (2002) 4.42
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42
Cdk1 is sufficient to drive the mammalian cell cycle. Nature (2007) 4.26
Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res (2006) 3.12
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res (2008) 2.64
Signaling interplay in Ras superfamily function. Curr Biol (2005) 2.59
Cell cycle kinases in cancer. Curr Opin Genet Dev (2007) 2.46
Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res (2005) 2.44
Prevalent mutations in prostate cancer. J Cell Biochem (2006) 2.12
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res (2002) 2.01
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res (1999) 1.80
Androgen receptors in prostate cancer. Endocr Relat Cancer (2002) 1.71
Ras signaling in prostate cancer progression. J Cell Biochem (2004) 1.62
Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem (2005) 1.59
Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res (2003) 1.56
KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. Am J Ther (2009) 1.56
Motility and invasion are differentially modulated by Rho family GTPases. Oncogene (2000) 1.55
Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev (2001) 1.53
Prenylation inhibitors in renal disease. Lancet (2000) 1.45
Characterization and cell cycle-regulated expression of mouse B-myb. Oncogene (1992) 1.22
Caveolin-1 expression is associated with high-grade bladder cancer. Urology (2001) 1.13
DNA methylation and apoptosis. Mol Immunol (2006) 1.13
Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol (2004) 1.10
Infrequent RAS oncogene mutations in human prostate cancer. Prostate (1992) 1.10
Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol (2006) 1.05
Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res (2011) 0.99
Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene (2003) 0.99
Liver prenylated methylated protein methyl esterase is the same enzyme as Sus scrofa carboxylesterase. J Biochem Mol Toxicol (2008) 0.93
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int J Oncol (2012) 0.93
Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med (2013) 0.92
Liver prenylated methylated protein methyl esterase is an organophosphate-sensitive enzyme. J Biochem Mol Toxicol (2005) 0.91
Impact of KRAS Mutations on Management of Colorectal Carcinoma. Patholog Res Int (2011) 0.87
KRAS mutation screening in colorectal cancer: From paper to practice. Clin Colorectal Cancer (2010) 0.85
Porcine Liver Carboxylesterase Requires Polyisoprenylation for High Affinity Binding to Cysteinyl Substrates. Open Enzym Inhib J (2009) 0.85
Polyisoprenylation potentiates the inhibition of polyisoprenylated methylated protein methyl esterase and the cell degenerative effects of sulfonyl fluorides. Curr Cancer Drug Targets (2011) 0.85
Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer (2013) 0.83
Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. Biomark Med (2010) 0.83
Regulation of polyisoprenylated methylated protein methyl esterase by polyunsaturated fatty acids and prostaglandins. Eur J Lipid Sci Technol (2011) 0.82
Polyisoprenylated methylated protein methyl esterase is both sensitive to curcumin and overexpressed in colorectal cancer: implications for chemoprevention and treatment. Biomed Res Int (2013) 0.82
Control of RhoA methylation by carboxylesterase I. J Biol Chem (2013) 0.82
Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs. Clin Lung Cancer (2004) 0.81
Inhibition of polyisoprenylated methylated protein methyl esterase by synthetic musks induces cell degeneration. Environ Toxicol (2012) 0.81
Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib. Prostate (2011) 0.81
Polyisoprenylated methylated protein methyl esterase overexpression and hyperactivity promotes lung cancer progression. Am J Cancer Res (2014) 0.81
Regulation and function of the cyclin-dependent kinase inhibitor p16CDKN2. Leukemia (1997) 0.76
Expression of cyclins A, D2 and D3 in individual normal mitogen stimulated lymphocytes and in MOLT-4 leukemic cells analyzed by multiparameter flow cytometry. Leukemia (1995) 0.76